HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to ph...

Full description

Saved in:
Bibliographic Details
Main Authors WANG, XIAODONG, BARTBERGER, MICHAEL D, DEIGNAN, JEFFREY, GUSTIN, DARIN J, OLSON, STEVEN H, EKSTEROWICZ, JOHN, MCINTOSH, JOEL, WEATHERS, CHRISTINE, BECK, HILARY PLAKE, HEATH, JULIE A, FU, JIASHENG, MEDINA, JULIO C, LI, ZHIHONG, FOX, BRIAN M, REW, YOSUP, MIHALIC, JEFFREY T, SUN, DAQING, GONZALEZ LOPEZ DE TURISO, FELIX, MA, ZHIHUA, CONNORS, RICHARD V, ROVETO, PHILIP M, DUQUETTE, JASON A, YAN, XUELEI, SCHMITT, MICHAEL J, CHEN, XIAOQI, KAYSER, FRANK, WANSKA, MALGORZATA, JOHNSON, MICHAEL G, GONZALEZ BUENROSTRO, ANA, LI, YIHONG, KOPECKY, DAVID J
Format Patent
LanguageEnglish
French
German
Published 16.11.2016
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
Bibliography:Application Number: EP20120775888